BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

898 related articles for article (PubMed ID: 17150303)

  • 41. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
    Wheler J; Johnson M; Seidman A
    Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hormone therapy in breast cancer: the end of tamoxifen?].
    Delozier T
    Bull Cancer; 2005 Feb; 92(2):142-50. PubMed ID: 15749643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
    Younus J; Vandenberg TA
    Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Breast cancer adjuvant endocrine therapy.
    Cigler T; Goss PE
    Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant endocrine therapy in breast cancer.
    Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
    Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
    Bauerschlag D; Schem C; Maass N; Jonat W
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
    Smith IE
    Breast; 2004 Dec; 13 Suppl 1():S3-9. PubMed ID: 15585377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?
    Burdette-Radoux S; Muss HB
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S37-41. PubMed ID: 19561005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
    Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD
    Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical practice decisions in endocrine therapy.
    Untch M; Thomssen C
    Cancer Invest; 2010; 28 Suppl 1():4-13. PubMed ID: 20653403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The choice of systemic adjuvant therapy in receptor-positive early breast cancer.
    Dellapasqua S; Castiglione-Gertsch M
    Eur J Cancer; 2005 Feb; 41(3):357-64. PubMed ID: 15691634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anastrozole for breast cancer: recent advances and ongoing challenges.
    Buzdar AU
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
    Goss PE
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extended adjuvant endocrine therapy of early breast cancer.
    Chowdhury S; Ellis P
    Curr Med Res Opin; 2005 Dec; 21(12):1985-95. PubMed ID: 16368050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
    Del Mastro L; Clavarezza M; Venturini M
    Cancer Treat Rev; 2007 Dec; 33(8):681-7. PubMed ID: 17850976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Menopausal symptoms and adjuvant therapy-associated adverse events.
    Hadji P
    Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.